Micro Imaging Technology, Inc. (MIT) announced the acquisition of Cellmyx, a company known for its quality medical tools in cosmetic surgery and regenerative medicine. This acquisition complements MIT's recent purchase of SaltMed/SaltFacial, enhancing its product portfolio and global manufacturing capabilities. Cellmyx specializes in autologous adipose grafting and has FDA clearance for its IntelliFat® BOD™ technology, which uses a patient's own fat for healing in orthopedic and cosmetic procedures. MIT aims to continue expanding in the aesthetics and regenerative medicine sectors, offering advanced medical solutions worldwide.
Toro Corp. announced the results of its shareholder election for a special dividend declared in April 2026. The dividend of $0.90 per share was paid on June 5, 2026, either in cash totaling about $3.8 million or in approximately 5.7 million common sh...
Students from the Midwest region won top honors at the 2026 Midwest Youth Entrepreneurship Showcases and will compete at the National Youth Entrepreneurship Showcase in New York City this November. Their ventures include AI platforms, storytelling ap...
Douglas Dynamics, a leading North American manufacturer of work truck attachments, announced a quarterly cash dividend of $0.295 per share for the second quarter of 2026. The dividend will be paid on June 30, 2026, to shareholders recorded by June 16...
True Health, a Chinese medical technology company specializing in robotic puncture and ablation devices, has filed for an IPO in Hong Kong to raise funds for product development and market expansion. The company leads China's small but fast-growing p...
Collegium Pharmaceutical awarded 50,305 restricted stock units (RSUs) on June 1, 2026, to 34 newly hired non-executive employees as an inducement to join the company. These RSUs will vest over three years, starting June 10, 2027, contingent on contin...
